Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
← catalyst calendarNCT07211178 · readout ≤ 2,326 d
Sponsored by Tempus AI (industry) · TEM — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
900estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-27 | actual | When the study began enrolling |
| Primary completion | Dec 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- HER2 + Breast Cancer
- Early Stage Breast Cancer
Intervention
- Other: There are no interventions in this observational study.
Primary outcome
what the primary-completion date above is the date OFInvasive Disease-Free Survival (iDFS) stratified by MRD status during neoadjuvant, post-surgery landmark, post definitive treatment (surveillance), and long-term follow-up
measured 5 years
Permalink · TEM's whole pipeline · Catalyst calendar · Every registered study · What changed